Replies to post #213035 on Biotech Values

[mcbio]

I resemble this comment in every aspect. My more costly investing mistakes have been selling too early rather than not taking profits, although I have a few instances of each. I'm willing to wait for the full value of the company to manifest, even if it takes a few years. Still like the risk/reward here relative to other places I could put the money to work.

Roxa China seems underappreciated, and the anti-fibrotic potential might be just unfolding. Still some good potential catalysts to come this year.

Agree with all of that. It could very well be a rocky ride but my gut is that if just one of roxa or pamrevlumab pans out as hoped for (and we now at least have clinical PoC for both drugs) over the course of the next couple of years, I feel pretty good about risk-reward from here. Given the significant rights FGEN has retained for both drugs (all rights in fact for pamrevlumab for now) and fact that both are addressing large market opportunities, I don't think both have to succeed to do well in the end (talking 2+ years out). Obviously if both flop in Phase 3, there is significant downside to be had but, given the strong PoC we now have for both, I'm willing to extend myself a bit more and gamble with the oversized position.